Company profile: Healx
1.1 - Company Overview
Company description
- Provider of AI-driven rare disease drug discovery and development, leveraging generative AI and machine learning to identify and repurpose drug candidates. Offerings include Healnet, preclinical testing, clinical trials, regulatory approval and access, and making approved treatments available to patients.
Products and services
- AI Drug Discovery: AI-driven system using generative AI and machine learning to discover treatments for rare diseases by enhancing existing drugs or identifying additional indications
- Healnet: Data-ingestion AI platform that ingests vast volumes of literature to identify potential drug candidates for rare diseases from published research
- Clinical Trials: Clinical-grade human studies evaluating the efficacy and safety of drug candidates following preclinical testing and preceding regulatory approval
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Healx
Nivalis
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceutical therapies designed to preserve intracellular S-nitrosoglutathione (GSNO), an endogenous molecule with cell signaling effects implicated in cystic fibrosis pathophysiology; developing a novel class of disease-modifying treatments, including lead candidate N91115 initially targeting CF patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nivalis company profile →
Attune Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapeutics, including ATN-249, an oral plasma kallikrein inhibitor for Hereditary Angioedema (HAE), and complement pathway inhibition approaches targeting the complement system to treat diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attune Pharmaceuticals company profile →
Wilson Therapeutics
HQ: Sweden
Website
- Description: Provider of biopharmaceutical R&D focused on rare diseases, developing Decuprate as a new treatment for Wilson Disease, currently in a Phase II clinical study; based in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wilson Therapeutics company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
Applied Genetic Technologies
HQ: United States
Website
- Description: Provider of AAV-based gene therapies, conducting human clinical trials for rare diseases. Offerings include AGTC-501, a Phase 2/3 gene therapy for X-Linked Retinitis Pigmentosa delivering full-length RPGR, preclinical AAV programs for dry age-related macular degeneration and cone rod dystrophy, and the VISTA Phase 2/3 trial evaluating AGTC-501.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Genetic Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Healx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Healx
2.2 - Growth funds investing in similar companies to Healx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Healx
4.2 - Public trading comparable groups for Healx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →